Metabolically Healthy Obesity
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis, and cancer. However, there is a large variation in the individual risk to developing obesity-associated comorbid diseases that cannot simply be explained by the extent of adiposity. Observations that a proportion of individuals with obesity have a significantly lower risk for cardiometabolic abnormalities led to the concept of metabolically healthy obesity (MHO). Although there is no clear definition, normal glucose and lipid metabolism parameters—in addition to the absence of hypertension—usually serve as criteria to diagnose MHO. Biological mechanisms underlying MHO lower amounts of ectopic fat (visceral and liver), and higher leg fat deposition, expandability of subcutaneous adipose tissue, preserved insulin sensitivity, and beta-cell function as well as better cardiorespiratory fitness compared to unhealthy obesity. Whereas the absence of metabolic abnormalities may reduce the risk of type 2 diabetes and cardiovascular diseases in metabolically healthy individuals compared to unhealthy individuals with obesity, it is still higher in comparison with healthy lean individuals. In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts—even in this subgroup—which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. Metabolically healthy obesity represents a model to study mechanisms linking obesity to cardiometabolic complications. Metabolically healthy obesity should not be considered a safe condition, which does not require obesity treatment, but may guide decision-making for a personalized and risk-stratified obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hyperplasia, referring to an increase in the number of adipocytes, is associated with an increase in subcutaneous fat volume and protective signals, and is associated with MHO (50).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, hypertrophic adipocytes, in which existing adipocytes enlarge, is associated with increased dysfunction and MUHO (50), which contributes to IR and subsequent T2D (52, 53).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126
Self-citationThe global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Cited by
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Self-citationThe aetiology and molecular landscape of insulin resistance
James, D. E., Stöckli, J., & Birnbaum, M. J. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00390-6 · Cited by 690
Lipid droplet biogenesis and functions in health and disease
Zadoorian, A., Du, X., & Yang, H. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00845-0 · Cited by 617
Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.06.012 · Cited by 564
Global pandemics interconnected — obesity, impaired metabolic health and COVID-19
Stefan, N., Birkenfeld, A. L., & Schulze, M. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00462-1 · Cited by 452
Obesity and the risk of cardiometabolic diseases
Valenzuela, P. L., Carrera-Bastos, P., Castillo-García, A., Lieberman, D. E., Santos-Lozano, A., & Lucia, A. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00847-5 · Cited by 452
Global burden of hematologic malignancies and evolution patterns over the past 30 years
Zhang, N., Wu, J., Wang, Q., Liang, Y., Li, X., Chen, G., Ma, L., Liu, X., & Zhou, F. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00853-3 · Cited by 432
“The updated criteria allow for earlier detection and identi fi cation of patients who may bene fi t from early treatment, but may also overestimate the incidence and mortality rates of this disease (with over 140,000 cases of MM diagnosed annually since 2015) [45, 46].”
Mitochondrial alterations in fatty liver diseases
Fromenty, B., & Roden, M. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2022.09.020 · Cited by 424
Reassessing human adipose tissue
Cypess, A. M. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2032804 · Cited by 404
Lopez-Jimenez, F., Almahmeed, W., Bays, H., Cuevas, A., Di Angelantonio, E., le Roux, C. W., Sattar, N., Sun, M. C., Wittert, G., Pinto, F. J., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwac187 · Cited by 362
Obesity, kidney dysfunction, and inflammation: interactions in hypertension
Hall, J. E., Mouton, A. J., da Silva, A. A., Omoto, A. C. M., Wang, Z., Li, X., & do Carmo, J. M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa336 · Cited by 265
“Others have proposed the concept of metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO) based on clinical observations that a subgroup of people with BMI >_ 30 do not exhibit obvious cardiometabolic abnormalities.(25,26) Fat location is important in determining cardiometabolic health and accu…”
BackgroundAn adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
Lee, E., Korf, H., & Vidal-Puig, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.01.024 · Cited by 222
Stefan, N., & Schulze, M. B. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00086-4 · Cited by 215
Bray, G. A. (2023) · Nutrients · doi:10.3390/nu15102254 · Cited by 210
Obesity I: Overview and molecular and biochemical mechanisms
Lustig, R. H., Collier, D., Kassotis, C., Roepke, T. A., Kim, M. J., Blanc, E., Barouki, R., Bansal, A., Cave, M. C., Chatterjee, S., et al. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115012 · Cited by 203
Metabolically healthy obesity: from epidemiology and mechanisms to clinical implications
Schulze, M. B., & Stefan, N. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01008-5 · Cited by 172
Blüher, M. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16263 · Cited by 175
“2,46 – 50 A better stratification of obesity subphenotypes may help to prioritise treatment strategies and to identify those people who may benefit the most from weight loss interventions.”
Self-citationRole of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes
Vilariño-García, T., Polonio-González, M., Pérez-Pérez, A., Ribalta, J., Arrieta, F., Aguilar, M., Obaya, J., Gimeno-Orna, J., Iglesias, P., Navarro, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25042338 · Cited by 170
Metabolic dysfunction and obesity‐related cancer: Beyond obesity and metabolic syndrome
Karra, P., Winn, M., Pauleck, S., Bulsiewicz‐Jacobsen, A., Peterson, L., Coletta, A., Doherty, J., Ulrich, C. M., Summers, S. A., Gunter, M., et al. (2022) · Obesity · doi:10.1002/oby.23444 · Cited by 168
“Behavior-based weight loss interventions result in significant weight reduction irrespective of macronutrient composition (68), improve metabolic dysfunction parameters, and reduce the risk of”
BackgroundRelevance of body composition in phenotyping the obesities
Salmón-Gómez, L., Catalán, V., Frühbeck, G., & Gómez-Ambrosi, J. (2023) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-023-09796-3 · Cited by 158
Zhou, Z., Macpherson, J., Gray, S. R., Gill, J. M. R., Welsh, P. I., Celis-Morales, C. A., Sattar, N. A., Pell, J. P., & Ho, F. K. W. (2021) · Diabetologia · doi:10.1007/s00125-021-05484-6 · Cited by 170
Huang, T., Song, J. G., Gao, J. L., Cheng, J. R., Xie, H., Zhang, L., Wang, Y., Gao, Z., Wang, X., Wang, X., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31126-5 · Cited by 176
Cardiometabolic characteristics of people with metabolically healthy and unhealthy obesity
Petersen, M. C., Smith, G. I., Palacios, H. H., Farabi, S. S., Yoshino, M., Yoshino, J., Cho, K., Davila-Roman, V. G., Shankaran, M., Barve, R. A., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.03.002 · Cited by 149
Watanabe, K., Wilmanski, T. M., Diener, C., Earls, J. C., Zimmer, A., Lincoln, B., Hadlock, J., Lovejoy, J. C., Gibbons, S. M., Magis, A. T., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02248-0 · Cited by 179
Drapkina, O. M., Васильевна, К. А., Калинина, А. М., Avdeev, S. M., Викторович, А. М., Alexandrova, L. M., Анциферова, А. А., Dm, A., Ахмеджанов, Н. М., Balanova, Y. А., et al. (2022) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2022-3235 · Cited by 231
Desoyé, G., & Herrera, E. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101082 · Cited by 142
The Interplay between Obesity and Inflammation
Săvulescu-Fiedler, I., Mihalcea, R., Dragosloveanu, Ş., Scheau, C., Baz, R. O., Căruntu, A., Scheau, A.-E., Căruntu, C., & Benea, S. N. (2024) · Life · doi:10.3390/life14070856 · Cited by 160
Peng, H., Pan, L., Ran, S., Wang, M., Huang, S., Zhao, M., Cao, Z., Yao, Z., Xu, L., Yang, Q., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1083032 · Cited by 120
“We cannot simply assume that high body weight and excessive fat accumulation indicate poor health status since there are phenotypes of metabolically healthy obese (MHO) and metabolically unhealthy non-obese (MUNO) (12, 13).”
BackgroundVisceral Adipose Tissue: The Hidden Culprit for Type 2 Diabetes
Dhokte, S., & Czaja, K. (2024) · Nutrients · doi:10.3390/nu16071015 · Cited by 132
“Despite their BMI, people with MHO do not often gain many health benefits from losing weight, though they are advised not to gain additional weight [37].”
BackgroundTrends in the Prevalence of Metabolically Healthy Obesity Among US Adults, 1999-2018
Wang, J., Xia, P., Ma, M., Li, Y., Geng, T., Zhang, Y., Tu, Z., Jiang, L., Zhou, L., Zhang, B.-F., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.2145 · Cited by 126
Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies
Lee, Y. A., & Friedman, S. L. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13380 · Cited by 107
Metabolically Healthy and Unhealthy Normal Weight and Obesity
Stefan, N. (2020) · Endocrinology and Metabolism · doi:10.3803/enm.2020.301 · Cited by 116
“Thus, while currently there is no broad agreement among the researchers and clinicians on how to define metabolic health (MH) [16-21], the definition proposed by Wildman et al.”
BackgroundRetinol-binding protein 4 in obesity and metabolic dysfunctions
Nankam, P. A. N., & Blüher, M. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111312 · Cited by 98
“However, the expansion of adipose tissue does not always translate into obesity-associated cardiometabolic diseases (Blüher, 2009b, 2013b, 2020; Lacobini et al., 2019; Rezaee and Dashty, 2013; Bosy-Westphal and Muller, 2021).”
BackgroundSelf-citationThe ambiguous role of obesity in oncology by promoting cancer but boosting antitumor immunotherapy
Assumpção, J. A. F., Pasquarelli-do-Nascimento, G., Viegas, M. S., Bonamino, M., & Magalhães, K. G. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00796-0 · Cited by 100
Adipose Tissue Macrophage Polarization in Healthy and Unhealthy Obesity
Ruggiero, A. D., Key, C.-C. C., & Kavanagh, K. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.625331 · Cited by 97
“and/or dyslipidemia, and cutoff criteria associated with each of these maladies define obesity as either healthy [metabolically healthy obese (MHO)] or unhealthy [metabolically unhealthy obese (MUO)] (6, 7).”
BackgroundUnveiling adipose populations linked to metabolic health in obesity
Reinisch, I., Ghosh, A., Noé, F., Sun, W., Dong, H., Leary, P., Dietrich, A., Hoffmann, A., Blüher, M., & Wolfrum, C. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.11.006 · Cited by 98
Self-citationSocioeconomic Status and Obesity
Autret, K., & Bekelman, T. A. (2024) · Journal of the Endocrine Society · doi:10.1210/jendso/bvae176 · Cited by 114
Gut microbiota is associated with metabolic health in children with obesity
Alcazar, M., Escribano, J., Ferré, N., Closa-Monasterolo, R., Selma‐Royo, M., Feliu, A., Castillejo, G., Luque, V., Closa-Monasterolo, R., Escribano, J., et al. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.06.007 · Cited by 88
Liu, X., Abudukeremu, A., Jiang, Y., Cao, Z., Wu, M., Ma, J., Sun, R., He, W., Chen, Z., Chen, Y., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01777-9 · Cited by 83
“Despite recent studies attempt to standardize the concept of metabolically healthy obesity, there is no unified definition of metabolically healthy obesity [79, 80].”
BackgroundInsulin and cancer: a tangled web
Leitner, B. P., Siebel, S., Akingbesote, N. D., Zhang, X., & Perry, R. J. (2022) · Biochemical Journal · doi:10.1042/bcj20210134 · Cited by 83
Chen, Y.-K., Liu, T.-T., Teia, F. K. F., & Xie, M.-Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218880 · Cited by 74
“Chronic stress significantly contributes to weight gain, as it can cause hormonal imbalances that increase appetite and decrease metabolism (116).”
BackgroundWang, Z., Zhao, S., Tao, S., Hou, G., Zhao, F.-L., Tan, S., & Meng, Q. (2023) · Molecules · doi:10.3390/molecules28062878 · Cited by 83
for the Metabolic Syndrome Study Group, Elías-López, D., Vargas‐Vázquez, A., Mehta, R., Bautista, I. C., Razo-Olvera, F. M. D., Gómez‐Velasco, D., Valdés, P. A., & Aguilar-Salinas, C. A. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00754-1 · Cited by 62
Obesity, Adipose Tissue, and Inflammation Answered in Questions
Guerreiro, V. A., Carvalho, D. M., & Freitas, P. (2022) · Journal of Obesity · doi:10.1155/2022/2252516 · Cited by 86
“Lifestyle factors also appear to play a key role in distinguishing whether an individual is MHO or not [117], which, in turn, influences, as an example, the polarization state of macrophages [109].”
BackgroundInfluentialBreaking Boundaries: Chronic Diseases and the Frontiers of Immune Microenvironments
Li, G., Wan, Y., Jiao, A., Jiang, K., Cui, G., Tang, J., Yu, S., Hu, Z., Zhao, S., Yi, Z., et al. (2025) · Med Research · doi:10.1002/mdr2.70007 · Cited by 63
Picolo, V. L., de Quadros, V. A., Canzian, J., Grisólia, C. K., Goulart, J. T., Pantoja, C., Bem, A. F. D., & Rosemberg, D. B. (2021) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2021.110288 · Cited by 70
Metabolically healthy obesity: Misleading phrase or healthy phenotype?
Tanrıöver, C., Çöpür, S., Gaipov, A., Özlüşen, B., Akcan, R. E., Kuwabara, M., Hornum, M., van Raalte, D. H., & Kanbay, M. (2023) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2023.02.025 · Cited by 70
Romero-Tapiador, S., Lacruz-Pleguezuelos, B., Tolosana, R., Freixer, G., Daza, R., Fernández-Díaz, C. M., Aguilar-Aguilar, E., Fernández-Cabezas, J., Cruz-Gil, S., Molina, S., et al. (2023) · Database · doi:10.1093/database/baad049 · Cited by 82
Castillo, Í. M. P., Argilés, J. M. A., Rueda, R., Ramírez, M., & Pedrosa, J. M. L. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09954-9 · Cited by 80
“Although not all obese individuals exhibit insulin resistance – a condition that some authors referred to as ‘metabolically healthy obesity’ [16] – and patients with T2DM are not invariably obese [17], compromised musculoskeletal health consistently emerges as a common hallmark in both conditions.”
rs7041 and rs4588 Polymorphisms in Vitamin D Binding Protein Gene (VDBP) and the Risk of Diseases
Rozmus, D., Płomiński, J., Augustyn, K., & Cieślińska, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020933 · Cited by 65
Agius, R., Pace, N. P., & Fava, S. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3725 · Cited by 73
“9,11,12 Conversely, individuals with normal ‐ range BMI who are hyper-insulinaemic and insulin resistant display a dysfunctional metabolic profile similar to that in obese individuals.”
BackgroundHalabitska, I., Бабинец, Л. С., Oksenych, V., & Kamyshnyi, O. (2024) · Biomedicines · doi:10.3390/biomedicines12081630 · Cited by 60
Metabolically (un)healthy obesity and risk of obesity-related cancers: a pooled study
Sun, M., Fritz, J., Häggström, C., Bjørge, T., Nagel, G., Manjer, J., Engeland, A., Zitt, E., Guelpen, B. R. V., Stattin, P. E., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad008 · Cited by 58
Scheidl, T. B., Brightwell, A. L., Easson, S., & Thompson, J. A. (2023) · BMC Medicine · doi:10.1186/s12916-023-02730-z · Cited by 65
White Adipose Tissue Dysfunction: Pathophysiology and Emergent Measurements
Santillana, N., Astudillo-Guerrero, C., D’Espessailles, A., & Cruz, G. (2023) · Nutrients · doi:10.3390/nu15071722 · Cited by 70
A phenome-wide comparative analysis of genetic discordance between obesity and type 2 diabetes
Coral, D., Fernandez-Tajes, J. J., Tsereteli, N., Pomares‐Millan, H., Fitipaldi, H., Mutie, P. M., Atabaki‐Pasdar, N., Kalamajski, S., Poveda, A., Miller‐Fleming, T. W., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-022-00731-5 · Cited by 54
Epidemiological link between obesity, type 2 diabetes mellitus and cancer
Fernandez, C. J., George, A. S., Subrahmanyan, N. A., & Pappachan, J. M. (2021) · World Journal of Methodology · doi:10.5662/wjm.v11.i3.23 · Cited by 63
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.002 · Cited by 52
Lin, C., Chang, Y., Cheng, T., Lo, K., Liu, S., & Yeh, T. (2020) · Obesity Reviews · doi:10.1111/obr.13049 · Cited by 57
Rolle-Kampczyk, U. E., Gebauer, S., Haange, S., Schubert, K. A., Kern, M., Moulla, Y., Dietrich, A., Schön, M. R., Klöting, N., von Bergen�, M., et al. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.142458 · Cited by 52
Self-citationKasahara, N., Imi, Y., Amano, R., Shinohara, M., Okada, K., Hosokawa, Y., Imamori, M., Tomimoto, C., Kunisawa, J., Kishino, S., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-46404-5 · Cited by 55
“Such attenuation of insulin resistance in a manner independent of fat mass is reminiscent of metabolic healthy obesity, characterized by obesity in the absence of metabolic and cardiovascular complications 38 .”
BackgroundEngin, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-63657-8_1 · Cited by 70
Not Only Metabolic Complications of Childhood Obesity
Ciężki, S., Odyjewska, E., Bossowski, A. T., & Głowińska‐Olszewska, B. (2024) · Nutrients · doi:10.3390/nu16040539 · Cited by 64
Mahamat‐Saleh, Y., Aune, D., Freisling, H., Hardikar, S. S., Jaafar, R. F., Rinaldi, S., Gunter, M. J., & Dossus, L. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02857-7 · Cited by 65
“Also, for some of the current fi ndings that were rated with high certainty and where few studies were included such as pancreas, gallbladder, and stomach, additional studies could potentially alter the results, however, we still consider this less likely as these are cancers with established…”
BackgroundObesity and Pregnancy, the Perfect Metabolic Storm
Corrales, P., Vidal-Puig, A., & Medina-Gómez, G. (2021) · European Journal of Clinical Nutrition · doi:10.1038/s41430-021-00914-5 · Cited by 51
“body fat accumulation, MHO is insulin sensitive and does not exhibit cardiometabolic complications [12, 16].”
BackgroundStrack, C., Behrens, G., Sag, S. J. M., Mohr, M., Zeller, J., Lahmann, C., Hubauer, U., Loew, T. H., Maier, L. S., Fischer, M., et al. (2022) · Biology of Sex Differences · doi:10.1186/s13293-022-00416-4 · Cited by 66
“Therefore, an altered and increased ectopic fat content around the liver and visceral organs in men [7, 8, 46] might be a more potent determinant of metabolic health as an increased body fat mass by itself [3, 47].”
BackgroundInfluentialVerdú, E., Homs, J., & Boadas‐Vaello, P. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182413333 · Cited by 67
Understanding Adipose Tissue Dysfunction
Blüher, M. (2024) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes24013 · Cited by 61
Self-citationHou, Z., Pan, Y., Yang, Y.-D., Yang, X., Xiang, X., Wang, Y., Li, Z., Zhao, X., Li, H., Meng, X., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.630140 · Cited by 46
“Although MHO criteria have not been clearly defined, normal glucose and lipid metabolism parameters, in addition to the absence of hypertension, is considered typical MHO diagnostic criteria (32).”
BackgroundObesity, obesities and gastrointestinal cancers
Zou, Y., & Pitchumoni, C. S. (2023) · Disease-a-Month · doi:10.1016/j.disamonth.2023.101592 · Cited by 56
MHO or MUO? White adipose tissue remodeling
Zhao, J. Y., Li, Z., Ma, K. L., Hao, R., & Li, M. (2024) · Obesity Reviews · doi:10.1111/obr.13691 · Cited by 49
Obesity, metabolic health and omics: Current status and future directions
Paczkowska‐Abdulsalam, M., & Kretowski, A. J. (2021) · World Journal of Diabetes · doi:10.4239/wjd.v12.i4.420 · Cited by 47
Wang, N., Sheng, Z., Zhou, S., Jiang, F., & Zhang, Z. (2022) · Food and Chemical Toxicology · doi:10.1016/j.fct.2022.113451 · Cited by 46
Cárdenas, J. K. Z., Azcona, C., Catalán, V., Ramírez, B., Silva, C., Rodríguez, A., Escalada, J., Frühbeck, G., & Gómez‐Ambrosi, J. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01972-8 · Cited by 51
Koliaki, C. C., Dalamaga, Μ., Kakounis, K., & Liatis, S. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00637-9 · Cited by 52
“…tissue function expressed as a favorable adipokine secretion profile, lower systemic and adipose tissue inflam - mation, a distinct pattern of circulating metabolites affecting whole-body insulin sensitivity, and higher cardiorespiratory fitness, when compared to subjects with MUO [ 20, 25, 34].”
Pi, P., Zeng, L., Zeng, Z., Zong, K., Han, B., Bai, X., & Wang, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1319827 · Cited by 48
The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies
Lysaght, J., & Conroy, M. J. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-01032-5 · Cited by 45
Krieg, L., Didt, K., Karkossa, I., Bernhart, S. H., Kehr, S., Subramanian, N., Lindhorst, A., Schaudinn, A., Tabei, S., Keller, M., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-324603 · Cited by 44
Self-citationSzczerbiński, Ł., & Florez, J. C. (2023) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(23)00232-2 · Cited by 45
Dietary trends and obesity in Saudi Arabia
Alhusseini, N. K., AlSinan, N. A., Almutahhar, S., Khader, M., Tamimi, R., Elsarrag, M., Warar, R., Alnasser, S., Ramadan, M. M., Omair, A. A., et al. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1326418 · Cited by 48
“A sedentary lifestyle and consumption of fast food play a role in weight gain (29), and an increase in BMI above 40 kg/m2 would reduce life expectancy up to 20 years (27).”
BackgroundReduced Olfactory Bulb Volume in Obesity and Its Relation to Metabolic Health Status
Poessel, M., Breuer, N., Joshi, A., Pampel, A., Villringer, A., Hummel, T. R., & Horstmann, A. (2020) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2020.586998 · Cited by 43
“Interestingly, not all individuals with obesity show significant alterations in their metabolic and endocrine systems, referring to the concept of metabolically “healthy” obesity (Blüher, 2020).”
BackgroundThe Pancreatic ß-cell Response to Secretory Demands and Adaption to Stress
Kalwat, M. A., Scheuner, D., Rodrigues-dos-Santos, K., Eizirik, D. L., & Cobb, M. H. (2021) · Endocrinology · doi:10.1210/endocr/bqab173 · Cited by 43
She, Y., Mangat, R., Tsai, S. J., Proctor, S. D., & Richard, C. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.840209 · Cited by 47
“MHO individuals can even exhibit improved insulin sensitivity, better adipose tissue function, a favorable adipokine secretion pattern, as well as less immune cell infiltrations into adipose tissue (21).”
BackgroundCzumaj, A., Śledziński, T., & Mika, A. (2022) · Nutrients · doi:10.3390/nu14112310 · Cited by 42
“The well-known hallmark of obesity is dyslipidemia [5,6].”
BackgroundObesity management: at the forefront against disease stigma and therapeutic inertia
Busetto, L., Sbraccia, P., & Vettor, R. (2021) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-021-01217-1 · Cited by 49
“This example recalls the case of obesity labelled as “healthy” when the disease is not accompanied by manifested and codified disorders of glucose and lipid metabolism and/or cardiovascular complications, despite several large observations demonstrating that individuals with “healthy” obesity are at a higher risk for…”
BackgroundShin, J., Li, T., Zhu, L., Wang, Q., Liang, X., Li, Y., Wang, X., Zhao, S., Li, L., & Li, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.859708 · Cited by 47
“…the other category is based on concomitant metabolic markers such as blood pressure, fasting glucose, triglycerides, (TG), and highdensity lipoprotein cholesterol (HDL-C); in addition, some scholars have used homeostasis models to assess insulin resistance or insulin sensitivity (Matthias, 2020).”
BackgroundObesity-Related Glomerulopathy: From Mechanism to Therapeutic Target
Wei, L., Li, Y., Yu, Y., Xu, M., Chen, H., Li, L., Peng, T., Zhao, K., & Zhuang, Y. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s334199 · Cited by 42
Barrachina, M. N., Pernes, G., Becker, I. C., Allaeys, I., Hirsch, T. I., Groeneveld, D. J., Khan, A. O., Freire, D., Guo, K., Carminita, E., et al. (2023) · Nature Cardiovascular Research · doi:10.1038/s44161-023-00305-y · Cited by 44
Carli, F., Sabatini, S., Gaggini, M., Sironi, A. M., Bedogni, G., & Gastaldelli, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914651 · Cited by 46
“…is less likely to accumulate ectopic fat and develop MASLD [6,11,12], whereas if subcutaneous fat does not expand, excess fat accumulates as intra-abdominal fat (e.g., visceral, hepatic, and pancreatic) and/or intra-thoracic fat (as epicardial, mediastinal, and/or intramyocardial fat) [11,13–16].”
A roadmap to the molecular human linking multiomics with population traits and diabetes subtypes
Halama, A., Zaghlool, S. B., Thareja, G., Kader, S. A., Al‐Muftah, W., Mook-Kanamori, M. J., Sarwath, H., Mohamoud, Y. A., Stephan, N., Ameling, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51134-x · Cited by 45
“Thisfurtherextendsourunderstanding of metabolically healthy obesity, characterized, among others, by high BMIand low insulin resistance 111 , whichto someextent is characteristic of MOD subgroup.”
Liang, W., & Ouyang, H. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01729-8 · Cited by 40
“Obesity, a global health concern, is intrinsically linked to a variety of health hazards, such as glucose intolerance [15], IR [16], and metabolic abnormalities [17], all of which can precipitate the onset, progression, and prognosis of cerebrovascular disease [18].”
BackgroundBaca, P., Barajas-Olmos, F. M., Mirzaeicheshmeh, E., Zerrweck, C., Guilbert, L., Sánchez, E. C., Flores-Huacuja, M., Villafán, R., Martínez-Hernández, A. G., Garcia‐Ortíz, H., et al. (2022) · Nutrition and Diabetes · doi:10.1038/s41387-022-00228-w · Cited by 39
“The mechanisms underlying these differences have been difficult to explain on the basis of factors related to lifestyle, environment, and genetic predisposition [4].”
BackgroundUllah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
Arabinoxylan Alleviates Obesity by Regulating Gut Microbiota and Bile Acid Metabolism
Lin, J., Liu, H., Sun, Y., Zou, J., Nie, Q., & Nie, S. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c06392 · Cited by 40
Fu, X., Wang, Y., Lu, Y. P., Liu, J., & Li, H. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123192 · Cited by 50
Anti-inflammatory agents as modulators of the inflammation in adipose tissue: A systematic review
Nascimento, S. S. D. C., de Queiroz, J. L. C., de Medeiros, A. F., Nunes, A. C. D. F., Piuvezam, G., Maciel, B. L. L., Passos, T. S., & Morais, A. H. D. A. (2022) · PLoS ONE · doi:10.1371/journal.pone.0273942 · Cited by 40
Artificial intelligence and body composition
Santhanam, P., Nath, T., Peng, C. Y., Bai, H. X., Zhang, H., Ahima, R. S., & Chellappa, R. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102732 · Cited by 36
Comparison of muscle mass and quality between metabolically healthy and unhealthy phenotypes
Kim, H., Lee, M. J., Kim, E. H., Bae, S., Kim, K. W., & Kim, C. (2021) · Obesity · doi:10.1002/oby.23190 · Cited by 38
“Longterm follow- up studies have reported that between one third and one half of individuals with the MHO phenotype convert to an unhealthy phenotype over time, which is associated with an increased cardiovascular disease risk (25,46).”
BackgroundMethodAkram, M., Ali, S. A., Behare, P. V., & Kaul, G. (2021) · Food & Function · doi:10.1039/d1fo02501e · Cited by 36
Lejawa, M., Osadnik, K., Czuba, Z. P., Osadnik, T., & Pawlas, N. (2021) · Life · doi:10.3390/life11121350 · Cited by 39
Metadata
- Authors
- Blüher, M.
- Affiliations
- Helmholtz Munich (DE)
- Corresponding author
- Blüher, Matthias
- ORCID
- Blüher, Matthias
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-03-04
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7098708
- OpenAlex
- W3009496837
- Cited by
- 1,090
- References
- 123
- Citations by year
- 2026: 197 · 2025: 222 · 2024: 213 · 2023: 162 · 2022: 155 · 2021: 105 · 2020: 35
- FWCI
- 86.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (209933838)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- metabolically healthy obesity, obesity, cardiometabolic risk, type 2 diabetes, cardiovascular disease, insulin sensitivity, beta-cell function, ectopic fat, visceral fat, liver fat, leg fat, cardiorespiratory fitness, weight loss, obesity treatment, risk stratification
- MeSH terms
- Obesity, Metabolically Benign, Cardiometabolic Risk Factors, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.